US9442116B2 - Method of predicting chemotherapeutic responsiveness of cancer - Google Patents
Method of predicting chemotherapeutic responsiveness of cancer Download PDFInfo
- Publication number
- US9442116B2 US9442116B2 US12/765,995 US76599510A US9442116B2 US 9442116 B2 US9442116 B2 US 9442116B2 US 76599510 A US76599510 A US 76599510A US 9442116 B2 US9442116 B2 US 9442116B2
- Authority
- US
- United States
- Prior art keywords
- formalin
- fixed paraffin
- clinical sample
- rna
- embedded clinical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims abstract description 38
- 206010028980 Neoplasm Diseases 0.000 title abstract description 24
- 230000000973 chemotherapeutic effect Effects 0.000 title abstract description 12
- 230000004043 responsiveness Effects 0.000 title abstract description 11
- 201000011510 cancer Diseases 0.000 title description 7
- 230000014509 gene expression Effects 0.000 claims abstract description 36
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 25
- 239000000243 solution Substances 0.000 claims description 11
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 8
- 239000012620 biological material Substances 0.000 claims description 8
- 239000008096 xylene Substances 0.000 claims description 8
- 239000002299 complementary DNA Substances 0.000 claims description 7
- 108010067770 Endopeptidase K Proteins 0.000 claims description 5
- 238000010240 RT-PCR analysis Methods 0.000 claims description 5
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 238000009396 hybridization Methods 0.000 claims description 3
- 239000000872 buffer Substances 0.000 claims description 2
- 239000007853 buffer solution Substances 0.000 claims description 2
- 239000003599 detergent Substances 0.000 claims 5
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 5
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 3
- 230000002934 lysing effect Effects 0.000 claims 2
- 230000001376 precipitating effect Effects 0.000 claims 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 abstract description 29
- 239000012188 paraffin wax Substances 0.000 abstract description 11
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract description 7
- 238000002493 microarray Methods 0.000 abstract description 7
- 206010033128 Ovarian cancer Diseases 0.000 abstract description 6
- 229930013930 alkaloid Natural products 0.000 abstract description 3
- 229940100198 alkylating agent Drugs 0.000 abstract description 3
- 239000002168 alkylating agent Substances 0.000 abstract description 3
- 230000000340 anti-metabolite Effects 0.000 abstract description 3
- 239000002256 antimetabolite Substances 0.000 abstract description 3
- 229940100197 antimetabolite Drugs 0.000 abstract description 3
- 229960004316 cisplatin Drugs 0.000 abstract description 3
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 abstract description 3
- 201000009030 Carcinoma Diseases 0.000 abstract description 2
- 230000005929 chemotherapeutic response Effects 0.000 abstract description 2
- 230000002068 genetic effect Effects 0.000 abstract description 2
- 239000003242 anti bacterial agent Substances 0.000 abstract 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 229940088710 antibiotic agent Drugs 0.000 abstract 1
- 239000000523 sample Substances 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 11
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 8
- 238000003491 array Methods 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 238000003753 real-time PCR Methods 0.000 description 5
- 238000003364 immunohistochemistry Methods 0.000 description 4
- 229910052697 platinum Inorganic materials 0.000 description 4
- 238000004393 prognosis Methods 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000010200 validation analysis Methods 0.000 description 3
- 239000011534 wash buffer Substances 0.000 description 3
- 102100034343 Integrase Human genes 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 201000004283 Shwachman-Diamond syndrome Diseases 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 239000003972 antineoplastic antibiotic Substances 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000003500 gene array Methods 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000013179 statistical model Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 238000010207 Bayesian analysis Methods 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 101710203526 Integrase Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 238000002790 cross-validation Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000002435 cytoreductive effect Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000013178 mathematical model Methods 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000011518 platinum-based chemotherapy Methods 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57449—Specifically defined cancers of ovaries
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/44—Multiple drug resistance
Definitions
- This invention relates to cancer diagnosis methods. Specifically, the invention is a method of determining the response of a cancer to chemotherapy using gene expressions of formalin-fixed paraffin embedded tissue samples.
- tissue banks are invaluable resources of tissues for translational studies of cancer and various other diseases. Accessibility of macromolecules in the samples is a critical issue, as FFPE samples are traditionally limited to IHC.
- a predictor for ovarian cancer response to platinum-based therapy is needed for use with stable patient samples, such as formalin fixed paraffin embedded samples.
- the gene expression may be obtained from any number of means known in the art, including without limitation, Polymerase Chain Reaction, ChIp, gene array, microarrays or quantitative-Polymerase Chain Reaction (Q-PCR), and reverse transcriptase Polymerase Chain Reaction (rt-PCR).
- the present method utilizes a novel genetic screen to identify genes that contribute to chemotherapeutic responsiveness, using formalin fixed paraffin embedded clinical samples.
- a microarray screen showed formalin fixed paraffin embedded samples can identify genes related to chemotherapeutic response with 86% efficiency.
- At least one threshold value is defined for classifying the gene expression levels.
- the extracted biological material is selected from the group consisting of DNA, RNA, protein, derivatives thereof, and fragments thereof.
- derivatives refer to processed variants of DNA, RNA, or proteins, which includes, without limiting the scope of the invention, transcripts.
- the disclosed method uses RNA to determine gene expression. Gene expression levels are determined from the biological material in the clinical sample and compared to the gene expression of the clinical sample with a gene expression of known clinical outcome, indicative of tumor outcome.
- the method is useful for predicting tumor responsiveness to chemotherapeutic treatment selected from the group consisting of alkylating agent, antimetabolite, plant alkaloid, and antitumor antibiotic. In further embodiments, the method is useful for predicting tumor responsiveness to cisplatin.
- the disclosed methods utilize Polymerase Chain Reaction, ChIp, gene array, microarrays, reverse transcriptase Polymerase Chain Reaction, and quantitative-Polymerase Chain Reaction to determine gene expression in some embodiments.
- the methods further generated a probeset list and tested the plurality of gene expressions in the clinical sample for gene expression using the probeset list.
- the probeset list was generated by providing a first probeset and testing the first probeset against gene expression data for a tumor cell with known chemotherapeutic outcome, wherein the gene expression data is compared to the known chemotherapeutic outcome.
- the chemotherapeutic treatment is selected from the group consisting of alkylating agent, antimetabolite, plant alkaloid, and antitumor antibiotic, and in more specific embodiments, the chemotherapeutic is cisplatin.
- “Patient” is used to describe an animal, preferably a human, to whom treatment is administered, including prophylactic treatment with the compositions of the present invention.
- a tumor prognosis predictor based on gene expression signatures of cancer cells.
- Gene expression data is used to identify a patient's tumor response to chemotherapeutic intervention.
- the invention uses cumulative expression information from a series of genes involved in the regulation of the cell cycle and the mitotic process. This information is then used to categorize tumor samples based on the chemotherapeutic responsiveness using a mathematical model and gene expression data derived from microarrays or quantitative-Polymerase Chain Reaction (Q-PCR) data.
- Q-PCR quantitative-Polymerase Chain Reaction
- Training set GeneChip results were subjected to ANOVA and Binary regression analysis to develop and test gene expression profiles associated with ovarian cancer platinum-responsiveness.
- the 115 probe set predictor shown in FIG. 1 , was used to test the patient samples.
- the Predictor correctly identified 27/33 (82%) platinum complete responders (CR) and 10/11 (91%) incomplete responders (IR) for an overall accuracy of 37/44 (84%) in leave-one-out cross validation.
- the 115 probe set predictor correctly identified 26/32 (81%) CR and 9/11 (82%) IR samples, with an overall accuracy of 35/43 (81%).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/765,995 US9442116B2 (en) | 2007-10-23 | 2010-04-23 | Method of predicting chemotherapeutic responsiveness of cancer |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98196307P | 2007-10-23 | 2007-10-23 | |
| PCT/US2008/080939 WO2009055559A1 (fr) | 2007-10-23 | 2008-10-23 | Procédé de prévision de réponse chimiothérapeutique d'un cancer |
| US12/765,995 US9442116B2 (en) | 2007-10-23 | 2010-04-23 | Method of predicting chemotherapeutic responsiveness of cancer |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2008/080939 Continuation WO2009055559A1 (fr) | 2007-10-23 | 2008-10-23 | Procédé de prévision de réponse chimiothérapeutique d'un cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| US20100292087A1 US20100292087A1 (en) | 2010-11-18 |
| US9442116B2 true US9442116B2 (en) | 2016-09-13 |
Family
ID=40580004
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US12/765,995 Expired - Fee Related US9442116B2 (en) | 2007-10-23 | 2010-04-23 | Method of predicting chemotherapeutic responsiveness of cancer |
Country Status (2)
| Country | Link |
|---|---|
| US (1) | US9442116B2 (fr) |
| WO (1) | WO2009055559A1 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015013547A1 (fr) * | 2013-07-24 | 2015-01-29 | Cedars-Sinai Medical Center | Utilisation de galnac-t13 comme marqueur dans le diagnostic du cancer du sein ou du côlon |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030225528A1 (en) * | 2002-03-13 | 2003-12-04 | Baker Joffre B. | Gene expression profiling in biopsied tumor tissues |
| US20060154250A1 (en) | 2002-12-17 | 2006-07-13 | Morris David W | Novel compositions and methods in cancer |
| US20070172844A1 (en) | 2005-09-28 | 2007-07-26 | University Of South Florida | Individualized cancer treatments |
-
2008
- 2008-10-23 WO PCT/US2008/080939 patent/WO2009055559A1/fr not_active Ceased
-
2010
- 2010-04-23 US US12/765,995 patent/US9442116B2/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030225528A1 (en) * | 2002-03-13 | 2003-12-04 | Baker Joffre B. | Gene expression profiling in biopsied tumor tissues |
| US20060154250A1 (en) | 2002-12-17 | 2006-07-13 | Morris David W | Novel compositions and methods in cancer |
| US20070172844A1 (en) | 2005-09-28 | 2007-07-26 | University Of South Florida | Individualized cancer treatments |
Non-Patent Citations (22)
| Title |
|---|
| Affimetrix GeneChip Human Genome U133 2.0 Arrays FAQ; http://www.affymetrix.com/support/help/faqs/hgu133-2/faq-7.jsp; accessed Jul. 13, 2012. * |
| Affymetrix, Inc., Apr. 2003; Data Sheet: GeneChip Human Genome Arrays; p. 2 for "human datasheet". |
| Affymetrix, Inc., Aug. 20, 2008; HG-U133-Plus-2 Probe Sequences, FATSA for the text file. |
| Aviel-Ronen et al. 2006. "Large Fragment Bst DNA Polymerase for Whole Genome Amplification of DNA From Formalin-Fixed Paraffin-Embedded Tissues." BMC Genomics. vol. 7. No. 312. pp. 1-10. |
| Collet et al. 1994. "The Identification of Nuclear and Mitochondrial Genes by Sequencing Randomly Chosen Clones from a Marsupial Mammary Gland cDNA Library." Biochem Genet. vol. 32. Nos. 5/6. pp. 181-190. |
| Cook et al. 2000. "Binary Response and Logistic Regression Analysis." Part of the Iowa State University NSF/ILI Project Beyond Traditional Statistical Methods. http://www.faculty.sbc.edu/bkirk/Biostatistics/course%20documents%20for%202006/Logistic%20Regression%20Analysis.doc. |
| Crockett et al. 2005. "Identification of Proteins From Formalin-Fixed Paraffin-Embedded Cells by LC-MS/MS." Laboratory Investigation. vol. 85. pp. 1405-1415. |
| Dressman et al. 2007. "An Integrated Genomic-Based Approach to Individualized Treatment of Patients with Advanced-Stage Ovarian Cancer" Journal of Clinical Oncology. vol. 25. No. 5. pp. 517-525. |
| Dressman et al.; Retraction of the article "An Integrated Genomic-Based Approach to Individualized Treatment of Patients With Advanced-Stage Ovarian Cancer"; J Clin Oncol 25:517-525, 2007; published Jan. 27, 2012. * |
| Dubeau et al. 1986. "Southern Blot Analysis of DNA Extracted From Formalin-Fixed Pathology Specimens." Cancer Research. vol. 46. pp. 2964-2969. |
| Fox et al. 1985. "Formaldehyde Fixation." J. Histochem. Cytochem. vol. 33. No. 8. pp. 845-853. |
| Genome Reference Consortium Feb. 2009; GeneChip Human Genome U133 Plus 2.0 Array for "gene sequence source" doc. |
| Hood et al. 2006. "Unravelling the Proteome of Formalin-Fixed Paraffin-Embedded Tissue." Briefings in Functional Genomics and Proteomics. vol. 5. No. 2. pp. 169-175. |
| International Search Report for PCT/US20081/080939 dated Jan. 5, 2009. |
| Kunkel et al. 1981. "Contact-Site Cross-Linking Agents." Mol. Cell. Biochem. vol. 34. pp. 3-13. |
| Nugen Technologies, Inc. "WT-Ovation FFPE RNA Amplification System V2." www.nugenine.com. User Guide. Catalog # 3400-12, 3400-60. Version 05.09.08. pp. i-18. |
| Nugen Technologies, Inc. 2007. "RNA Sample Quality Assessment Test for the WT-Ovation FFPE System." www.nugenine.com. |
| Roche. 2008. "High Pure RNA Paraffin Kit." www.roche-applied-science.com. Cat. No. 03 270 289 001. pp. 1-24. |
| Shedden et al. 2008. "Gene Expression-Based Survival Prediction in Lung Adenocarcinoma: a Multi-Site, Blinded Validation Study." Nat. Med. vol. 14. No. 8. pp. 822-827. |
| Shi et al. 1991. "Antigen Retrieval in Formalin-Fixed, Paraffin-Embedded Tissues: an Enhancement Method for Immunohistochemical Staining Based on Microwave Oven Heating of Tissue Sections." J. Histochem Cytochem. vol. 39. No. 6. pp. 741-748. |
| Shi et al. 2002. DNA Extraction from Archival Formalin-Fixed, Paraffin-Embedded Tissue Sections Based on the Antigen Retrieval Principle: Heating Under the Influence of pH. The Journal of Histochemistry & Cytochemistry. vol. 50. No. 8. pp. 1005-1011. |
| West et al.; Predicting the clinical status of human breast cancer by using gene expression profiles; PNAS; vol. 98, No. 20, 11462-11467; Sep. 25, 2001. * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20100292087A1 (en) | 2010-11-18 |
| WO2009055559A1 (fr) | 2009-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6666852B2 (ja) | 前立腺がん再発の予後に関する遺伝子発現パネル | |
| KR101530689B1 (ko) | 직장결장암용 예후 예측 | |
| KR101566368B1 (ko) | 암 검출을 위한 소변 유전자 발현 비율 | |
| JP4435259B2 (ja) | 微量胃癌細胞の検出法 | |
| US20080318801A1 (en) | Method and kit for evaluating rna quality | |
| JP2011525106A (ja) | 瀰漫性ｂ大細胞型リンパ腫のマーカーおよびその使用方法 | |
| US7056673B2 (en) | Preservation of RNA in a biological sample | |
| CN106868204A (zh) | 一种用于胃腺癌诊断的生物标志物 | |
| Sigdel et al. | Targeted transcriptional profiling of kidney transplant biopsies | |
| US20120004127A1 (en) | Gene expression markers for colorectal cancer prognosis | |
| CN112646885B (zh) | 肾细胞癌miRNA分子标志物及其应用 | |
| CN104769130A (zh) | 一种确定rna完整性的方法 | |
| CN112553335A (zh) | 肾细胞癌生物标志物及其应用 | |
| KR101182974B1 (ko) | 림프종 진단 또는 예후 마커로서 Ｐｅｌｌｉｎｏ 1 | |
| US9442116B2 (en) | Method of predicting chemotherapeutic responsiveness of cancer | |
| Bartlett | Approaches to the analysis of gene expression using mRNA: a technical overview | |
| KR102503293B1 (ko) | 간독성 민감성 진단용 바이오마커 조성물 및 이를 이용한 예측 방법 | |
| JP4317854B2 (ja) | 微量胃癌細胞の検出法 | |
| CN113403382B (zh) | Ube2f在诊治股骨头坏死中的应用 | |
| US20240052422A1 (en) | In-vitro method for diagnosing and predicting the aggressiveness of thyroid cancer, and the precision surgery options and type to be used to remove a tumour from a patient; kit; reagents forming the kit; and use of the reagents and use of molecular markers as part of the method | |
| JP2022076117A (ja) | 前立腺がんを検査する方法 | |
| CN114032308A (zh) | Fam83a、kpna2、krt6a和ldha联合作为肺腺癌生物标志物的用途 | |
| KR20060087977A (ko) | 폐암 진단용 마커 | |
| KR102717762B1 (ko) | 개에서의 비결핵 항산균의 감염 진단을 위한 숙주 바이오마커 및 이의 이용 | |
| US11913062B2 (en) | System and method for isolation and qualification of nucleic acids |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: UNIVERSITY OF SOUTH FLORIDA, FLORIDA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:LANCASTER, JOHNATHAN M.;REEL/FRAME:024472/0178 Effective date: 20100527 |
|
| AS | Assignment |
Owner name: US ARMY, SECRETARY OF THE ARMY, MARYLAND Free format text: CONFIRMATORY LICENSE;ASSIGNOR:H. LEE MOFFITT CANCER CTR & RESEARCH INS;REEL/FRAME:025666/0027 Effective date: 20100510 |
|
| ZAAA | Notice of allowance and fees due |
Free format text: ORIGINAL CODE: NOA |
|
| ZAAB | Notice of allowance mailed |
Free format text: ORIGINAL CODE: MN/=. |
|
| STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
| MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, MICRO ENTITY (ORIGINAL EVENT CODE: M3551); ENTITY STATUS OF PATENT OWNER: MICROENTITY Year of fee payment: 4 |
|
| FEPP | Fee payment procedure |
Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: MICROENTITY |
|
| LAPS | Lapse for failure to pay maintenance fees |
Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: MICROENTITY |
|
| STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
| FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20240913 |